drugset / Trial / NCT05915247
Single Ascending Doses of HER-096 in Healthy Subjects
Phase 1
Completed
60 enrolled
Herantis Pharma Plc.
Clinical Research Services Turku - CRST Oy · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This study evaluates the safety and tolerability of HER-096 in healthy volunteer subjects by comparing the effects of active study treatment HER-096 to placebo (0.9% physiological saline). In addition, the pharmacokinetic profile of HER-096 in humans will be investigated. The investigational medicinal products will be administered as a single dose by subcutaneous injection.
Timeline
- Start
- 2023-03-29
- Primary completion
- 2023-09-29
- Completion
- 2023-09-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HER-096 | Unknown | — | Subcutaneous |